New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic COVID-19, with no severe disease or deaths with AZD7442 Separate treatment trial showed 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onsetNew data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination. In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300mg